Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.
Thermo Fisher reported revenue of $11.4 billion, up about 5% year-over-year and better than the $11.28 billion Visible Alpha consensus. Profit narrowly beat estimates at $1.83 billion, or $4.78 per share, up from $4.20 a year ago. Adjusted earnings per share (EPS) of $6.10 also topped expectations.
Sales increased across all four of the company's divisions, with revenue at its largest segment, Laboratory Products and Biopharma Services, rising 4%. Last quarter, shares fell as sales were flat or declined in two segments.
Thermo Fisher shares were up 6.6% intraday after entering Thursday roughly flat over the prior 12 months.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。